# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **₹1,806.1 Cr** Q3 FY'26 · **Operating EBITDA:** **₹96.8 Cr** (5.4% margin) (includes ₹70.59 Mn nonrecurring charge) * **Pharmacy Revenue:** **15.6% YoY growth** · **Operating EBITDA:** **₹925 Mn** (5.2% margin) * **Diagnostics Revenue:** **₹326.7 Mn** Q3 FY'26 (+43%) · **Operating EBITDA:** **₹50.7 Mn** (15.5% margin) * Store-Level EBITDA Margin: 12.6% (>24 months) · 8.8% (13–24 months) · 5.8% (all non-store costs allocated, >12 months) * **Net Working Capital:** **53 days** (↓~10 days YoY) · **Warehouse Inventory:** **34 days** ## B. Revenue & EBITDA * **Diagnostics Strength:** Diagnostics segment delivered robust double-digit revenue growth and margin expansion, now contributing meaningfully to consolidated EBITDA. * **Pharmacy Resilience:** Pharmacy business maintained stable margins despite moderate top-line growth, reflecting pricing discipline and cost control. * **Margin Pressure from One-Time Costs:** Consolidated EBITDA margin compressed due to **₹6 Cr nonrecurring charge** linked to Labour Code implementation, masking underlying operational improvement. * **Store Maturity Driving Profitability:** Store-level EBITDA margins show clear operating leverage, with newer stores achieving margin parity when corporate costs are allocated. ## C. Cash Flow & Working Capital * **Working Capital Efficiency:** Significant YoY improvement in working capital days driven by **franchisee model adoption**, which removes inventory from the balance sheet. * **Inventory Divergence:** First-year stores carry **103 days of inventory**, highlighting initial stocking needs, versus **35 days** for mature stores, indicating efficient turnover post-ramp. --- # 2. Store & Network Expansion ## A. Key Figures * **New Stores Opened:** **228** (QoQ) · **Closed:** **46** (QoQ) · **Net Additions:** **182** (QoQ) ## B. New Store Openings * **Cluster-Led Expansion:** Store growth driven by a cluster-based densification strategy, prioritizing penetration in existing states and efficient use of warehouse infrastructure before entering adjacent markets like Chhattisgarh and Kerala. * **Strategic Closures & Transitions:** Nearly **40% of closures** involved relocations or conversion to franchisee-operated models, reflecting network optimization and strategic realignment. ## C. Franchisee Growth * **Franchise Program in Evaluation Phase:** Expansion initiative ongoing with multiple models and partners under assessment; formal updates and financial reporting expected post full-year results. ## D. Warehouse Utilization * **Warehousing Ramp-Up Nears Completion:** **60–70% of new warehouses** are operational, with full deployment expected within two quarters and **manpower recruitment finalized**, signaling minimal future expense pressure from this stream. --- # 3. Sales Growth & Mix ## A. Key Figures * **Revenue (Stores >12 Months):** **₹1,630 Cr**, 96% of pharmacy revenues * Store-Level EBITDA Margin: 12.4% for stores >12 months * **Daily Gross Plan Sales:** **506 (Oct)** → **529 (Nov)** → **528 (Dec)** * **On-Time Renewal Rate:** **23%** in Q3 (vs. 24% prior) * **Active Plans / Lives:** **180,000 plans** covering **368,000 lives** (Dec 31) ## B. SSSG Trends * **SSSG Improvement Driven by Incentive Realignment:** Revised store incentives now reward total sales (branded + private label), contributing to **5% SSSG growth** despite prior focus on private label alone. * **Favorable Base Effect Supporting Growth:** Recent SSSG gains partially aided by easier prior-year comparisons, with management indicating potential for stabilization or improvement over next 3–4 quarters. * **Data Transparency Constraints:** MRP growth metrics for new stores (<12 months) suspended due to GST-related distortions (5–7% artificial drop), affecting comparability. ## C. Metro vs. Non-Metro * **Strategic Shift to Smaller Cities:** Sales contribution from Tier 2/3 and non-metro cities is rising as metro share declines, potentially fueled by stronger private label adoption in underserved markets. ## D. Online & Serviceability * **Online Membership Growth:** Active health plans increased by **10,000** and covered lives by **17,000** in Q3, reflecting sustained demand for integrated healthcare offerings. * **Enhanced E-Pharma Capabilities:** Serviceability for online pharmacy orders is being upgraded to compete with quick commerce, signaling strategic investment in digital fulfillment. --- # 4. Product & Private Label ## A. Key Figures * Private Label Revenue Mix: 22.2% total revenue (pharma 11.6% and FMCG 10.6%) * Private Label GMV (Pharma): 18.9% in Q3 FY'26 (vs. 7.9% pre-launch) * **Gross Margin (Pharma PL):** **65–70%** * **Gross Margin (Non-Pharma PL):** **25–30%** * **Non-Pharma SKUs:** **Over 1,300** * **Therapy Coverage:** **55 chronic**, **40–45 acute** conditions ## B. Pharma Private Label * **Strategic Scale with Margin Advantage:** Private label pharma delivers **65–70% gross margins** and spans both acute and chronic therapies, reinforcing profitability and clinical relevance. * **Customer Stickiness via Incentives:** Over **46–47 lakh members** drive repeat business, attracted by trade discounts on private label and enhanced savings on branded products. * **Inventory Strategy Adjusted for Availability:** MedPlus maintains dual inventory (branded + private label) to ensure full product availability, delaying SKU rationalization despite growth in private label adoption. ## C. Non-Pharma Expansion * **Portfolio-Led Growth:** Expansion into **food, wellness, and cold-pressed oils** is gaining traction, broadening the addressable market and supporting recurring revenue potential. * **Balanced Incentive Model Driving Dual Growth:** Revised incentives focused on total sales are boosting both **branded pharma** and **private label non-pharma** performance. * **High-Quality, Affordable Essentials:** Non-pharma range spans daily wellness and household needs with **over 1,300 SKUs**, emphasizing value and quality to drive volume. ## D. SKU & Therapy Mix * **Comprehensive Therapeutic Coverage:** Product portfolio spans **all top five WHO-listed therapeutic areas**, including diabetics and cardiovascular, enhancing relevance in chronic care. --- # 5. Cost & Margin Drivers ## A. Key Figures * **Corporate Expense Impact:** **₹7 Cr** one-time, nonrecurring charge (past service costs) * **Retention Scheme Payouts:** **₹18,000** (Year 1) and **₹50,000** (Year 2) per qualifying employee * **Branded Product Margins:** **13–14%** gross margin (reported net basis) for branded pharma and non-pharma * **Pharmacy Operating Margin:** **5–6%** (adjusted for one-time cost); target of **~6%** in next 2 years * **Pharmacy Gross Margin:** **~25%** (current level), with upside from private label mix ## B. Corporate Expenses * **One-Time Cost Explained:** Material increase in corporate expenses primarily due to **₹7 Cr nonrecurring charge** from new Wage Codes; run rate expected to normalize. * **Retention Program Under Review:** 3-year employee retention scheme active in three cities, with staggered payouts indicating cash flow discipline and performance-based evaluation. ## C. Inventory Write-offs * **Ongoing Operational Item:** Quarterly write-offs occur for non-pharmacy private label inventory, though no material impact reported; mitigation plans in place but not detailed. ## D. Gross Margin Trends * **Stable Outlook:** Gross margins held strong and are expected to remain resilient in 4Q and FY27, supported by favorable product mix dynamics. * **Private Label Accretion:** Growth in non-pharma private label delivers **incremental sales and accretive gross margins**, despite pharma private label margin pressure. * **Margin Hierarchy Confirmed:** Branded products yield **13–14%** net gross margins, while pharmacy-level gross margins sit at **~25%**, with structural upside from private label expansion. --- # 6. Risks & Margin Pressures ## A. Private Label Realization * **Sharp Decline in Realization:** Net realization on private label pharma has significantly contracted due to higher blended discounts, creating a challenging base for performance assessment. * **Stabilization Expected:** Management anticipates normalization over the next few quarters, which will enable more accurate evaluation of underlying business trends. --- # 7. Guidance & Outlook ## A. Margin Targets * **No Formal Guidance:** Company refrains from providing top-line, mix, or long-term private label penetration targets; aspirational goals exist but remain undisclosed. * **Margin Expansion Pathway:** Confidence in achieving **6% margin** over time, driven by private label scale benefits across a **5,000-store network** enabling favorable procurement economics. * **Structural Leverage:** General goods contribute only **20% of current sales**—below peers at 30–50%—highlighting substantial runway for margin-accretive private label growth. * **Incentive Framework Intact:** Prior linkage between **+50 bps private label penetration** and margin accretion remains valid; no updates to assumptions provided. ## B. Store Expansion Plan * **Expansion Intent:** FY27 store additions expected to be **at least similar** to current year’s pace, reflecting internal growth aspirations despite lack of formal guidance. * **Execution Focus:** Prioritization on improving store-level and backend efficiency ahead of aggressive scaling, as network maturity evolves.